Drug intelligence / Profile preview

FavId

Development stage: Phase 3
Lead developer: Favrille
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

FavId is an investigational therapeutic cancer vaccine developed for the treatment of B-cell non-Hodgkin lymphoma. It is a patient-specific, active immunotherapy designed to stimulate the immune system to recognize and attack malignant B cells by targeting the idiotype protein expressed on their surface. The vaccine consists of recombinant idiotype protein derived from each patient's tumor, combined with an adjuvant (GM-CSF) to enhance immune response. Its mechanism of action involves inducing a targeted immune response against lymphoma cells bearing the unique idiotype antigen.

Brand names: FavId
Other names: FavId

Targets

Id (Tumor-specific idiotype immunoglobulin)

Beyond the preview

Go deeper on FavId.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FavId.

Explore the full profile